NeoGenomics, Inc. filings document the regulatory record of an oncology diagnostics company whose common stock trades on Nasdaq under the symbol NEO. Form 8-K reports furnish quarterly and annual operating results, preliminary financial information, press release exhibits, and Regulation FD disclosures tied to the company’s clinical testing and diagnostic services business.
The company’s proxy materials cover board structure, director matters, executive compensation, equity awards, pay-versus-performance disclosures and annual meeting governance. Other material-event filings describe officer transitions, board appointments and resignations, and registered security information, including common stock par value and exchange listing details.
NeoGenomics, Inc. (NEO) reported third-quarter revenue of $209.3 million, compared with $187.8 million a year earlier, while net loss narrowed to $7.5 million from $27.1 million. For the nine months ended September 30, 2026, revenue was $597.6 million and net loss was $22.4 million, versus $537.2 million and $98.1 million, respectively, in 2025. Operating cash flow was $2.9 million for the nine-month period, compared with $3.9 million.
On June 22, 2026, NeoGenomics issued $316.3 million aggregate principal amount of 0.75% convertible senior notes due 2032, generating approximately $305.7 million in net proceeds. It used offering proceeds to repurchase a portion of its 2028 notes for $262.9 million and repurchased 2,383,222 common shares for $25.0 million. On July 20, 2026, NeoGenomics paid $10.0 million in a civil settlement with the U.S. Department of Justice on behalf of the HHS Office of Inspector General concerning consulting services under its Laboratory Collaboration Initiative. The settlement resolved the investigation, required no corporate integrity agreement or additional ongoing compliance obligations, and was not an admission of liability.
NeoGenomics, Inc. (NEO) reported third-quarter 2026 revenue of $209 million, up 11% year over year; clinical revenue grew 13% to $195 million and NGS revenue grew 29%. GAAP gross margin was 46.2%, compared with 42.8% a year earlier, while GAAP net loss narrowed to $8 million from $27 million. Adjusted EBITDA, a non-GAAP measure, increased 53% to $19 million from $12 million. Clinical test volume grew 2%, and average revenue per clinical test rose 11% to $530.
The company raised full-year 2026 guidance to $807 million–$809 million in revenue and approximately $60 million in adjusted EBITDA; its net loss guidance is $(32) million to $(30) million. Operating cash flow for the nine months ended September 30, 2026, was $2.937 million, versus $3.887 million in 2025. NeoGenomics said Warren Stone, its President and COO, is to become CEO and a board member effective January 4, 2027, when CEO Tony Zook is to transition to Executive Chairman. Medicare coverage for RaDaR ST was expanded to include immunotherapy treatment response monitoring in late-stage solid tumors, its third covered indication.
NeoGenomics Inc. President and Chief Operating Officer Warren Stone exercised 17,562 restricted stock units on October 1, 2026, acquiring 17,562 common shares. The issuer withheld 6,911 common shares to satisfy tax obligations related to the RSU release; no Rule 10b5-1 plan is reported. His disclosed direct options include options for 166,113 underlying shares at $11.21, expiring December 1, 2029, and options for 253,378 underlying shares at $10.81, expiring March 1, 2036.
NeoGenomics (NEO) announced that Warren Stone, its President and Chief Operating Officer, will become CEO and a Board member effective January 4, 2027; Tony Zook will become Executive Chairman then. Lynn Tetrault will step down as Chair, remain an independent director until the 2027 annual meeting, and has stated she does not intend to stand for reelection; Michael Kelly will become Lead Independent Director. A bylaw amendment increased the Board’s maximum size from 10 to 11 directors.
NeoGenomics expects preliminary, unaudited third-quarter 2026 revenue of approximately $209 million, including approximately 28% year-over-year NGS revenue growth. It reiterated full-year total revenue and adjusted EBITDA guidance issued July 28, 2026, and said full-year revenue guidance is expected to increase at the midpoint as a result of third-quarter performance; further details are expected on the third-quarter earnings call. The estimate remains subject to quarter-end closing procedures and adjustments. Stone’s agreement sets an $850,000 annual base salary, subject to adjustment, and eligibility for annual equity awards beginning in FY 2027 with an approximately $8,000,000 aggregate target value, at Compensation Committee discretion.
NeoGenomics, Inc. (NEO) executive Alicia C. Olivo reported one routine tax-related share disposition and updated her equity award holdings. On September 1, 2026, 2,692 shares of common stock were surrendered to NeoGenomics for retirement to satisfy tax obligations upon the vesting of restricted stock, leaving her with 90,875 common shares held directly. The filing also details her outstanding stock options, restricted stock units, and performance stock units across multiple grant dates, with exercise prices ranging from $9.45 to $48.99 and expirations extending to 2036, and no Rule 10b5-1 trading plan is reported.
NEOGENOMICS INC (NEO) reported that officer Warren Stone, President & Chief Operating Officer, exercised 28,106 Restricted Stock Units into an equal number of shares of common stock on August 21, 2026. On the same date, 11,060 shares of common stock were delivered or withheld for payment of exercise price or tax liability. The filing also lists Mr. Stone’s remaining equity incentives, including multiple tranches of stock options, restricted stock units, and performance stock units that vest over future dates and, once vested, common shares that are not subject to expiration.
First Light Asset Management, LLC and Mathew P. Arens report their beneficial ownership of NeoGenomics, Inc. common stock. First Light Asset Management may be deemed to beneficially own 10,260,186 shares, representing 7.99% of the common stock. These shares are held in separately managed accounts and private funds for which the Manager serves as investment adviser.
Mathew P. Arens may be deemed to beneficially own 10,759,586 shares, or 8.37% of the common stock, including 235,000 shares held directly with sole control and 264,400 shares in a joint account with shared control. Voting and dispositive powers are primarily shared through the Manager. The reporting persons state that these disclosures are made solely for purposes of Section 13(d) of the Exchange Act and are not an admission of beneficial ownership for other purposes.
NeoGenomics, Inc. reported that Alicia Olivo, Executive Vice President, General Counsel & Business Development, will transition from her role and cease to serve as General Counsel effective September 21, 2026. She will remain an employee through October 2, 2026 for transitional purposes.
The company states that, in connection with her departure, Ms. Olivo will be eligible to receive separation payments and benefits in line with Section 5(b) of her employment agreement, which had been filed previously as part of NeoGenomics’ Form 10-K for the year ended December 31, 2025.
NeoGenomics Inc. chief accounting officer Greg D. Aunan reported selling 20,000 shares of Common Stock on 2026-08-04 at $16.07 per share, leaving 5,153 shares held directly. He continues to hold multiple equity awards, including restricted stock units for 10,745 underlying shares and stock options for 28,662, 26,978, 31,163 and 36,825 underlying shares with exercise prices between $9.83 and $14.62.
NEO has a shareholder filing to sell 20,000 shares of common stock, with an aggregate market value of $321,480.00, through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with a proposed sale date of August 4, 2026.
The filing also lists multiple tranches of common stock underlying restricted stock vesting under a registered plan for services rendered, with vesting dates from May 1, 2024 through May 2, 2026 and share amounts ranging from 1,606 to 4,448.